The April 1, 2015 article by Klotz et al, entitled, “Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT,” (J Clin Oncol 33:1151-1156, 2015) was published with an error.
There was a discrepancy in the quoted P values between the text and Table 2.
In the Results section, third paragraph, the first sentence was given as: “There was a significant difference among the three testosterone groups in time to CRPC (P = .024; Figs 2A to 2C).” However, it should have been given as “There was a significant difference among the three testosterone groups in time to CRPC (P = .015; Table 2; Figs 2A to 2C).
Also in the third paragraph of the Results section, the third sentence was given as:
“Similarly, those patients with a median testosterone level > 0.7 nmol/L had a higher risk of developing CRPC (P = .01;..).” However, it should have been, “Similarly, those patients with a median testosterone level > 0.7 nmol/L had a higher risk of developing CRPC (P = .02;..).”
In the Results section, fourth paragraph, the first sentence was given as: “CSS was significantly different among the three groups (P = .015).” However, it should have been “CSS was significantly different among the three groups (P = .02).”
In Table 2, under the median (time to death resulting from prostate cancer), the last two numbers of “8.93” and “10.00” should have been “NR”, “NR” instead.
This has been corrected as of May 5, 2016. The authors apologize for the mistake.